Clinical trials: High-Risk Prostate Cancer, open to volunteers
Prostate Cancer
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of…
- Trial name
- NCT06059118
- Testing
- DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
The goal of this clinical trial is to evaluate whether adjuvant darolutamide plus androgen-deprivation therapy (ADT) can reduce post-operative recurrence and improve disease control in high-risk prostate cancer patients-defined…
- Trial name
- NCT07282197
- Testing
- Darolutamide (BAY 1841788)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University First Hospital
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer
Salvage HDR for Locally Recurrent Prostate Cancer
The study offers focal salvage brachytherapy for prostate cancer patients with a local recurrence after primary defintive radiotherapy
- Trial name
- PROSALBRA (NCT04231006)
- Testing
- High dose rate brachytherapy
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Localized Prostate Cancer
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized…
- Trial name
- 62SPECIAL (NCT07792993)
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Regina Elena Cancer Institute
Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy)
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA).
- Conditions
- Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostatic Neoplasms
- Trial name
- HYP-OP-RT (NCT07483658)
- Testing
- Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT)
- Where
- 4 sites in Canada
- Volunteers
- 434 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and…
- Trial name
- PSMA-ADJUVO (NCT06449781)
- Testing
- Lutetium (177Lu) vipivotide tetraxetan
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Prostate CA, Prostate Cancer (Adenocarcinoma)
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in…
- Conditions
- Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
- Trial name
- NCT06631521
- Testing
- Darolutamide, Relugolix, Radical Prostatectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- AdventHealth
Prostate Cancer
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate…
- Trial name
- NCT06565247
- Testing
- [18F]PSMA-PET, MRI sequences optimized for prostate cancer examinations
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Region Västerbotten
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant…
- Trial name
- NCT06613100
- Testing
- Xaluritamig, GnRH Antagonist
- Where
- 9 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Amgen
High Risk Prostate Cancer
Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.
This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate…
- Trial name
- NCT07208240
- Testing
- Tb-PSMA-I&T (Tb-PSMA)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
- Trial name
- HEATWAVE (NCT06067269)
- Testing
- Apalutamide, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Detection of Minimal Residual Disease Post-prostatectomy
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to…
- Trial name
- MiRaDE (NCT07334275)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy can fight prostate cancer by androgen deprivation.
- Trial name
- NCT04894188
- Testing
- radiation therapy, Goserelin 3.6 MG, radical prostatectomy
- Where
- 2 sites in Taiwan
- Volunteers
- 38 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer (Adenocarcinoma)
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
- Trial name
- NCT07182279
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Adenocarcinoma
INSPIRE: INnovative SABR for Prostate Cancer All IREland
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer.
- Trial name
- NCT07552168
- Testing
- Next generation Stereotactic Ablative Radiotherapy (SABR)
- Where
- 4 sites in Ireland, United Kingdom
- Volunteers
- 136 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
This pilot randomized, single-blind, placebo-controlled study evaluates the feasibility, safety, and preliminary biological activity of neoadjuvant intraprostatic onabotulinumtoxinA (BOTOX®) administered before radical…
- Trial name
- NCT07796490
- Testing
- OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute